BS_C7N3J4NW
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 163.00919842312746
- age_years
- 15.521
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.478
- PANCREAS_BETA_CELLS+0.364
- MYOGENESIS+0.304
- SPERMATOGENESIS+0.263
- HEDGEHOG_SIGNALING+0.242
- APICAL_SURFACE+0.229
- ESTROGEN_RESPONSE_LATE+0.115
- ESTROGEN_RESPONSE_EARLY+0.112
- APICAL_JUNCTION+0.090
- BILE_ACID_METABOLISM+0.042
Top 10 suppressed
- MYC_TARGETS_V1-0.671
- E2F_TARGETS-0.614
- MYC_TARGETS_V2-0.579
- G2M_CHECKPOINT-0.573
- UNFOLDED_PROTEIN_RESPONSE-0.560
- INTERFERON_ALPHA_RESPONSE-0.547
- DNA_REPAIR-0.538
- PROTEIN_SECRETION-0.531
- MTORC1_SIGNALING-0.474
- INTERFERON_GAMMA_RESPONSE-0.459
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KPT2WPHW | Ganglioglioma | — | 0.984 |
| 2 | BS_3T6X4BPC | DNET | — | 0.978 |
| 3 | BS_SM8VQFPD | DNET | — | 0.974 |
| 4 | BS_6MY8W3H0 | DNET | — | 0.973 |
| 5 | BS_CQSAJ7BF | DNET | — | 0.968 |
| 6 | BS_K5802F84 | pilocytic astrocytoma | — | 0.965 |
| 7 | BS_QV51J756 | Ganglioglioma | — | 0.965 |
| 8 | BS_MF47B9ZW | Ganglioglioma | — | 0.964 |
| 9 | SRR1418127 | GTEX | — | 0.962 |
| 10 | SRR1388378 | GTEX | — | 0.962 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.478 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.364 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.304 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.263 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.242 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.229 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.115 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.112 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.042 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.024 | Inavolisib | — uncovered |